Objective
to report the 5-year clinical outcomes of use of the AMPLATZER Amulet left atrial appendage occluder compared with the Watchman 2.5 device
Study
prospective multicentre randomised trial
Population
patients with non-valvular atrial fibrillation at high risk of stroke/embolism (CHADS2 score 2 or CHA2DS2-VASc score 3)
Endpoints
1) stroke/embolism 2) stroke/embolism/death 3) TIA 4) all-cause death
Conclusion
At 5 years of clinical follow-up, there were no significant clinical adverse outcome differences between the Amulet occluder and Watchman device.
Lakkireddy et al. J Am Coll Cardiol. 2025 Mar 25;85(11):1141-1153.